BioSpace News Archive

Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced that Jesse Ledger, Nuvo’s President & Chief Executive Officer will present at the H.C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City.

Vifor Pharma announced that Standard & Poor’s assigned a BBB- credit rating with stable outlook to Vifor Pharma.

One in four Canadian men (28 per cent) fear their job could be at risk if they discussed their mental health at work, according to new research by Movember.

Biocare Medical, LLC, a leading provider of innovative, automated immunohistochemistry (IHC) instrumentation and reagents, announces the release of a new mouse monoclonal antibody, p16 INK4a, for in vitro diagnostic (IVD) use in the qualitative identification of the p16 INK4a protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues.

Zoetis Inc. today announced that its scientists presented positive efficacy data for the company’s investigational, triple combination parasiticide product at the 2019 Triennial meeting of the American Heartworm Society (AHS) in New Orleans, La.

Aeromics, Inc. (“Aeromics” or “the Company”), a privately-held, clinical-stage pharmaceutical company developing first-in-class anti-edema therapies, announced today the appointment of Peter Agre, M.D. to its Board of Directors

The Bulfinch Companies, Inc. (Bulfinch), a private, real estate investment, development and management firm, today announced it has signed three new leases with Arbor Biotechnologies (Arbor), Kintai Therapeutics (Kintai) and Simcere Innovation, Inc. (Simcere) in Building 400‐500 at Cambridge Discovery Park (CDP), Bulfinch’s life sciences development in Cambridge, Massachusetts.

AXON Neuroscience SE has announced the results of the Phase II trial for AADvac1, its first-in-class vaccine to slow down the progression of Alzheimer’s Disease.

Encompass Health Corporation announced the pricing of its underwritten public offering of $500 million in aggregate principal amount of its 4.500% senior notes due 2028 at a public offering price of 100% of the principal amount and $500 million in aggregate principal amount of its 4.750% senior notes due 2030 at a public offering price of 100% of the principal amount.